San Diego, CA -- (SBWIRE) -- 12/30/2011 -- Vincent G. Brichard, Senior Vice President and Head of the Immunotherapeutics Business Unit at GlaxoSmithKline Biologicals will give a keynote presentation on the “Development of Active Immunization against Cancer: The Example of MAGE-A3” at the Immunotherapeutics Partnering and Deal-making Conference to be held in San Diego, CA on January 30-31, 2012 by GTC.
Dr. Brichard will present GSK’s progress in research and development. Highlights of his presentation include:
1) Their early and late clinical development of Immunotherapeutic assets in Oncology
2) Areas of collaboration and development opportunities for potential partners.
3) The success factors required to start the approach
4) The clinical, regulatory and potential commercial challenges faced in the context of the development of a new class of products that may introduce a change in cancer treatment
Vincent Brichard is Senior Vice President and Head of the Immunotherapeutics Business Unit at GSK Biologicals in Rixensart, Belgium. In 1986, Dr Brichard joined the Brussels branch of the Ludwig Institute for Cancer Research. As part of this group that identified the first tumor-specific antigens in humans, Dr. Brichard studied tumor inmmunology and obtained his PhD. He was then trained as a Medical Doctor in Internal Medicine, Oncology, at the Cliniques Universitaires Saint-Luc in Brussels, Belgium and as a Medical oncologist at the Oncology Department of the Institute Curie in Paris, France. In 2002, he joined GSK Biologicals to lead the Cancer Immunotherapeutics program. In 2006, a Business Unit was created to regroup under the same roof activities including R&D, Clinical, Regulatory and Commercial strategies.
The Immunotherapeutics Partnering and Deal-making Conference is an immunotherapeutics business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant immunotherapeutics issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about immunotherapeutics business development trends, the market, and novel technologies that shape up the industry.
This conference is also part of the Novel Immunotherapeutics Summit, which consists of this track and three other tracks:
1) 4th Immunotherapeutics and Immunomonitoring
2) 10th Cytokines and Inflammation
3) Allergy Drug Discovery and Development
For more information, please visit http://www.gtcbio.com